The efficacy of anti-PD1 antibodies in preventing malignant transformation has been demonstrated in carcinogen-induced OPMD mice, where effector T cell activation, STAT1 activation, and secretion of IFNγ and granzyme B have been demonstrated (10, 51–55). This evidence concerns the gene STAT1 and oculopharyngeal muscular dystrophy.